Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

AIMS/INTRODUCTION: Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has not been elucidated. In this study, we investigated t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Diabetes Investig
Päätekijät: Miyoshi, Arina, Kameda, Hiraku, Nagai, So, Nakamura, Akinobu, Miya, Aika, Takase, Takahiro, Atsumi, Tatsuya, Miyoshi, Hideaki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264394/
https://ncbi.nlm.nih.gov/pubmed/33141482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13458
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia